---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-163060"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:26:08.003769+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Teva concludes nationwide opioids settlement up to $4.25B; resolves all 50 states and >99% subdivisions

## Summary
- Teva will pay up to $4.25B over 13 years, including $1.2B of generic Narcan (or $240M cash) to participating states and subdivisions.
- Separate settlement with Nevada for $193M over 20 years, averting trial scheduled for August 2023.
- Settlement becomes effective August 7, 2023; first payments expected in H2 2023, with Narcan shipments already begun.
- Teva has now resolved opioid claims with all 50 U.S. states and more than 99% of litigating subdivisions and special districts.
- Agreement includes no admission of wrongdoing; company avoids further litigation uncertainty.

## SEC filing metadata
- accession: 0001193125-23-163060
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312523163060/0001193125-23-163060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312523163060/d461805d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-163060
- JSON: https://secwatch.observer/filing/0001193125-23-163060.json
- Plain text: https://secwatch.observer/filing/0001193125-23-163060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.